Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Corcept Therapeutics Stock Hit the Bricks Today

By Cory Renauer - Nov 20, 2019 at 5:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's fight to keep generic competition at bay took a turn for the worse.

What happened

Shares of Corcept Therapeutics ( CORT -2.33% ), a biopharmaceutical company, plunged today after investors learned the U.S. Patent and Trademark Office (USPTO) will consider arguments from Teva Pharmaceuticals ( TEVA -1.35% ). Investors worried about the threat this poses to Korlym, Corcept's only revenue stream, hammered the stock 22.1% lower on Wednesday.

So what 

Korlym is a tablet the Food and Drug Administration approved in 2012 for the treatment of hyperglycemia caused by Cushing's syndrome. Previously, the FDA approved Korlym's active ingredient, mifepristone, for the termination of early stage pregnancies in 2000. In other words, Korlym's a lot older than it looks.

Businesspeople looking at a fallen colleague.

Image source: Getty Images.

Seven years of orphan drug exclusivity ended this February, prompting Teva Pharmaceuticals, the world's largest generic drugmaker, to try marketing a generic version of the decades-old drug. Corcept's stock tanked today because the USPTO officially scheduled a post-grant review of patent 214.

Now what

A post-grant review is a path taken to invalidate an existing patent that is similar to an inter partes review with two key differences. A post-grant review petition must be filed within nine months of the patent's birthday, and it allows the plaintiff to challenge the patent's validity with arguments that cover a lot more ground.

Patent challenges fail more often than they succeed, but the situation doesn't look good for Corcept. The 214 patent covers a warning and dose adjustment instructions on Korlym's drug label that physicians would need to follow when prescribing a cheaper generic version.

Korlym is potentially dangerous to some patients because it inhibits CYP3A, an enzyme tasked with clearing a very long list of drugs from the bloodstream, including statins. Since Korlym is one of many drugs with dosages that physicians regularly adjust to address CYP3A-related interactions, there's a better-than-average chance the 214 patent won't survive Teva's challenge.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corcept Therapeutics Incorporated Stock Quote
Corcept Therapeutics Incorporated
$20.91 (-2.33%) $0.50
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$8.05 (-1.35%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.